Last 12 months
Inside the activity.
0 purchase rows · 83 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 7 |
| Dec 2025 | 0 | 31 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 27 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 8 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 02, 2026 Filed Mar 4, 2026 21:28 UTC |
Krainer Adrian R.Director
|
SaleCommon Stock | 7,229 | $39.66 | $286,715.15 |
DisclosureSEC source: 0001780081-26-000002 · form4-03042026_090337.xml · nonDerivative · entry 1 Krainer Adrian R. · CIK 0001780081 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,545 F1 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 15, 2025. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.50 to $39.80 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:25 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-26-000002 · form4-02192026_090252.xml · derivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-02-15 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3 · derivative.exercise_date: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:25 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $31.09 | $0.00 |
DisclosureSEC source: 0001780088-26-000002 · form4-02192026_090252.xml · derivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:24 UTC |
SMITH IAN FDirector · Chief Executive Officer
|
GrantRestricted Stock Units · Derivative | 129,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001197032-26-000002 · form4-02192026_090250.xml · derivative · entry 2 SMITH IAN F · CIK 0001197032 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,000 Underlying: Common Stock · 129,000 shares Expires 2030-02-15 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3 · derivative.exercise_date: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:24 UTC |
SMITH IAN FDirector · Chief Executive Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 193,000 | $0.00 Strike: $31.09 | $0.00 |
DisclosureSEC source: 0001197032-26-000002 · form4-02192026_090250.xml · derivative · entry 1 SMITH IAN F · CIK 0001197032 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 193,000 Underlying: Common Stock · 193,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:22 UTC |
Leggett ThomasChief Financial Officer
|
GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001774690-26-000002 · form4-02192026_090230.xml · derivative · entry 2 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-02-15 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3 · derivative.exercise_date: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:22 UTC |
Leggett ThomasChief Financial Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $31.09 | $0.00 |
DisclosureSEC source: 0001774690-26-000002 · form4-02192026_090230.xml · derivative · entry 1 Leggett Thomas · CIK 0001774690 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:20 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
GrantRestricted Stock Units · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-26-000002 · form4-02192026_090202.xml · derivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2030-02-15 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3 · derivative.exercise_date: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:20 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 53,000 | $0.00 Strike: $31.09 | $0.00 |
DisclosureSEC source: 0001966716-26-000002 · form4-02192026_090202.xml · derivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Stock · 53,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:21 UTC |
Hoitt JasonChief Patient Officer
|
GrantRestricted Stock Units · Derivative | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001762572-26-000002 · form4-02192026_090202.xml · derivative · entry 2 Hoitt Jason · CIK 0001762572 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,000 Underlying: Common Stock · 48,000 shares Expires 2030-02-15 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the issuer's common stock upon settlement. F3 · derivative.exercise_date: The RSU award shall vest as to 1/4 of the total award annually with the first tranche vesting on February 15, 2027, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:21 UTC |
Hoitt JasonChief Patient Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 72,000 | $0.00 Strike: $31.09 | $0.00 |
DisclosureSEC source: 0001762572-26-000002 · form4-02192026_090202.xml · derivative · entry 1 Hoitt Jason · CIK 0001762572 · Chief Patient Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 72,000 Underlying: Common Stock · 72,000 shares Expires 2036-02-16 F1 · derivative.exercise_date: The option shall vest as to 1/48 of the total award on March 15, 2026, with 1/48 vesting on each monthly anniversary thereafter, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:16 UTC |
LEVIN ARTHUR ADirector
|
Exercise / conversionRestricted Stock Units · Derivative | 1,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001181556-26-000003 · form4-01052026_090116.xml · derivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,211 shares Expires 2025-12-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement. F2 · derivative.exercise_date: The award vested or vests as to 1/4 of the total award quarterly on the last day of March, June, September, and December, subject to the reporting person's continued service to the issuer through each vesting date. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:16 UTC |
LEVIN ARTHUR ADirector
|
Exercise / conversionCommon Stock | 1,211 | $0.00 | $0.00 |
DisclosureSEC source: 0001181556-26-000003 · form4-01052026_090116.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,842 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:24 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
SaleCommon Stock | 2,678 | $32.61 | $87,337.08 |
DisclosureSEC source: 0001966716-25-000009 · form4-12102025_091230.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,831 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.29 to $33.19 per share, inclusive. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:24 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
SaleCommon Stock | 1,300 | $31.60 | $41,074.28 |
DisclosureSEC source: 0001966716-25-000009 · form4-12102025_091230.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,509 F1 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.27 to $32.14 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnote 3 of this Form 4. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:23 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 1,331 | $33.10 | $44,061.56 |
DisclosureSEC source: 0001522780-25-000010 · form4-12102025_091241.xml · nonDerivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,124 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.00 to $33.25 per share, inclusive. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:23 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 8,274 | $32.52 | $269,070.48 |
DisclosureSEC source: 0001522780-25-000010 · form4-12102025_091241.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,455 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.95 per share, inclusive. Read SEC document |
| December 08, 2025 Filed Dec 10, 2025 21:23 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 3,825 | $31.44 | $120,253.03 |
DisclosureSEC source: 0001522780-25-000010 · form4-12102025_091241.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 58,729 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.00 to $31.90 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 2 and 3 of this Form 4. Read SEC document |
| December 05, 2025 Filed Dec 6, 2025 01:51 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
SaleCommon Stock | 1,989 | $31.35 | $62,345.80 |
DisclosureSEC source: 0001780088-25-000006 · form4-12062025_011222.xml · nonDerivative · entry 5 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,798 F5 · kind: The transaction reported on this Form 4 was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 11, 2024. Read SEC document |
| December 05, 2025 Filed Dec 6, 2025 01:51 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
SaleCommon Stock | 1,673 | $31.33 | $52,415.76 |
DisclosureSEC source: 0001780088-25-000006 · form4-12062025_011222.xml · nonDerivative · entry 4 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,787 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive. Read SEC document |
| December 05, 2025 Filed Dec 6, 2025 01:50 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 500 | $31.85 | $15,923.00 |
DisclosureSEC source: 0001522780-25-000009 · form4-12062025_011216.xml · nonDerivative · entry 6 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,554 F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.70 to $31.96 per share, inclusive. Read SEC document |
| December 05, 2025 Filed Dec 6, 2025 01:50 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 1,681 | $31.15 | $52,357.77 |
DisclosureSEC source: 0001522780-25-000009 · form4-12062025_011216.xml · nonDerivative · entry 5 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 63,054 F5 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.69 to $31.61 per share, inclusive. Read SEC document |
| December 05, 2025 Filed Dec 6, 2025 01:50 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 6,367 | $31.33 | $199,480.66 |
DisclosureSEC source: 0001522780-25-000009 · form4-12062025_011216.xml · nonDerivative · entry 4 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,735 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive. Read SEC document |
| December 05, 2025 Filed Dec 6, 2025 01:49 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
SaleCommon Stock | 2,344 | $31.76 | $74,444.74 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · nonDerivative · entry 6 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,809 F5 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.59 to $31.97 per share, inclusive. Read SEC document |
| December 05, 2025 Filed Dec 6, 2025 01:49 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
SaleCommon Stock | 5,437 | $31.08 | $168,997.18 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · nonDerivative · entry 5 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,153 F5 · kind: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2024. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.58 to $31.57 per share, inclusive. Read SEC document |
| December 05, 2025 Filed Dec 6, 2025 01:49 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
SaleCommon Stock | 1,004 | $31.33 | $31,455.72 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · nonDerivative · entry 4 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,590 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.93 to $31.69 per share, inclusive. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:51 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
SaleCommon Stock | 323 | $31.32 | $10,115.20 |
DisclosureSEC source: 0001780088-25-000006 · form4-12062025_011222.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,460 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:51 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
SaleCommon Stock | 1,373 | $30.76 | $42,238.29 |
DisclosureSEC source: 0001780088-25-000006 · form4-12062025_011222.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,783 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 and 4 of this Form 4. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:50 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 1,231 | $31.32 | $38,550.49 |
DisclosureSEC source: 0001522780-25-000009 · form4-12062025_011216.xml · nonDerivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,102 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:50 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 5,222 | $30.76 | $160,647.00 |
DisclosureSEC source: 0001522780-25-000009 · form4-12062025_011216.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,333 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3, 4, 6, and 7 of this Form 4. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:49 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
SaleCommon Stock | 194 | $31.32 | $6,075.38 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · nonDerivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,594 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.23 to $31.505 per share, inclusive. Read SEC document |
| December 04, 2025 Filed Dec 6, 2025 01:49 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
SaleCommon Stock | 824 | $30.76 | $25,349.12 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,788 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.23 to $31.19 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3, 4, 6, and 7 of this Form 4. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 01:23 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
SaleCommon Stock | 1,225 | $30.85 | $37,788.43 |
DisclosureSEC source: 0001780088-25-000005 · form4-12042025_011237.xml · nonDerivative · entry 5 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,156 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 01:23 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
SaleCommon Stock | 789 | $30.34 | $23,936.68 |
DisclosureSEC source: 0001780088-25-000005 · form4-12042025_011237.xml · nonDerivative · entry 4 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,381 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 01:22 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 651 | $30.85 | $20,081.85 |
DisclosureSEC source: 0001522780-25-000008 · form4-12042025_011205.xml · nonDerivative · entry 5 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,305 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 01:22 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 419 | $30.34 | $12,711.62 |
DisclosureSEC source: 0001522780-25-000008 · form4-12042025_011205.xml · nonDerivative · entry 4 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,956 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 01:20 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
SaleCommon Stock | 1,394 | $30.85 | $43,001.69 |
DisclosureSEC source: 0001966716-25-000006 · form4-12042025_011223.xml · nonDerivative · entry 5 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,612 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F5 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.815 to $31.17 per share, inclusive. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 01:20 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
SaleCommon Stock | 898 | $30.34 | $27,243.52 |
DisclosureSEC source: 0001966716-25-000006 · form4-12042025_011223.xml · nonDerivative · entry 4 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,006 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.81 to $30.805 per share, inclusive. Read SEC document |
| December 03, 2025 Filed Dec 6, 2025 01:51 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
Exercise / conversionPerformance Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-25-000006 · form4-12062025_011222.xml · derivative · entry 6 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F7 · derivative.exercise_date: Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| December 03, 2025 Filed Dec 6, 2025 01:51 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
Exercise / conversionCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001780088-25-000006 · form4-12062025_011222.xml · nonDerivative · entry 1 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2025 Filed Dec 6, 2025 01:50 UTC |
Kaye Edward M. MDDirector
|
Exercise / conversionPerformance Stock Units · Derivative | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001522780-25-000009 · form4-12062025_011216.xml · derivative · entry 7 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 26,250 shares Expires 2025-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F9 · derivative.exercise_date: Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| December 03, 2025 Filed Dec 6, 2025 01:50 UTC |
Kaye Edward M. MDDirector
|
Exercise / conversionCommon Stock | 26,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001522780-25-000009 · form4-12062025_011216.xml · nonDerivative · entry 1 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,555 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2025 Filed Dec 6, 2025 01:49 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
Exercise / conversionPerformance Stock Units · Derivative | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · derivative · entry 7 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires 2025-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. F9 · derivative.exercise_date: Half the award vested on December 3, 2024 and the remainder vested or vests on December 3, 2025, subject to the reporting person's continued service to the Issuer on the relevant vesting date. Read SEC document |
| December 03, 2025 Filed Dec 6, 2025 01:49 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
Exercise / conversionCommon Stock | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001966716-25-000008 · form4-12062025_011219.xml · nonDerivative · entry 1 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,612 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 01:23 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
SaleCommon Stock | 762 | $30.14 | $22,968.13 |
DisclosureSEC source: 0001780088-25-000005 · form4-12042025_011237.xml · nonDerivative · entry 3 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,170 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 01:23 UTC |
Ticho BarryCHIEF MEDICAL OFFICER
|
SaleCommon Stock | 1,244 | $29.56 | $36,775.13 |
DisclosureSEC source: 0001780088-25-000005 · form4-12042025_011237.xml · nonDerivative · entry 2 Ticho Barry · CIK 0001780088 · CHIEF MEDICAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,932 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 01:22 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 405 | $30.14 | $12,207.47 |
DisclosureSEC source: 0001522780-25-000008 · form4-12042025_011205.xml · nonDerivative · entry 3 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,375 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 01:22 UTC |
Kaye Edward M. MDDirector
|
SaleCommon Stock | 661 | $29.56 | $19,540.48 |
DisclosureSEC source: 0001522780-25-000008 · form4-12042025_011205.xml · nonDerivative · entry 2 Kaye Edward M. MD · CIK 0001522780 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,780 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 01:20 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
SaleCommon Stock | 868 | $30.14 | $26,163.17 |
DisclosureSEC source: 0001966716-25-000006 · form4-12042025_011223.xml · nonDerivative · entry 3 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,904 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.93 to $30.63 per share, inclusive. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 01:20 UTC |
Allan JonathanGENERAL COUNSEL & CORP SEC
|
SaleCommon Stock | 1,416 | $29.56 | $41,859.79 |
DisclosureSEC source: 0001966716-25-000006 · form4-12042025_011223.xml · nonDerivative · entry 2 Allan Jonathan · CIK 0001966716 · GENERAL COUNSEL & CORP SEC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,772 F1 · kind: The reported transaction represents an Issuer mandated sale to satisfy tax withholding liabilities in connection with the vesting and settlement of restricted stock units. F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.93 to $29.92 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.